Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-101 and iTOL-102: Developing a Potential Cure for Type 1 Diabetes
iTOL-101 utilizes allogeneic cadaveric pancreatic islets in combination with iTOL-100 and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, Insulin-Dependent Diabetes, pancreatic islets derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our iTOL-102 program leverages significant advancements in stem cells to derive human pancreatic islets which allows an inexhaustible supply of insulin-producing cells and is being developed as a potential cure for Type 1 Diabetes.
Development Pipeline
1: Development of iTOL-401 is subject to the entry of a license agreement with Georgia Tech Research Corporation
Patient Journeys
Patients, caregivers and family members share their real-life experiences in living with Type 1 Diabetes.
We Were 1 of 3 Companies Selected to Participate in the Disruptive Healthcare
Technology Showcase at the US Capitol on June 12, 2023.
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Releases Next Video in Its Patient Journey Series Highlighting the Real-Life Impact of Type 1 Diabetes
Watch the next video segment here MIAMI, FL / ACCESS Newswire / December 3, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced...
iTolerance CEO, Anthony Japour, Receives BioFlorida’s Research & Developer of the Year Award
MIAMI, FL / ACCESS Newswire / November 12, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, Chief...
iTolerance CEO, Anthony Japour, Receives BioFlorida’s Research & Developer of the Year Award
MIAMI, FL / ACCESS Newswire / November 12, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, Chief...